<DOC>
	<DOCNO>NCT01390064</DOCNO>
	<brief_summary>Objective - Determine safety tolerability peptide mimotope-based vaccine upon immunization breast cancer subject .</brief_summary>
	<brief_title>Vaccination High Risk Breast Cancer Patients</brief_title>
	<detailed_description>After sign Institutional Review Board ( IRB ) approve consent , cohorts 3-6 stage IV breast cancer subject enrol study . The vaccine dose prepared dispensed University Arkansas Medical Sciences ( UAMS ) Pharmacy follow manufacturer 's instruction . Subjects receive 1.0 mL subcutaneous ( SC ) injection vaccine 5 separate occasion Weeks 1 , 2 , 3 , 7 , 19 . The first cohort begin 300 mg dose , subsequent cohort escalate 500 mg de-escalate 100 mg determine toxicity criterion . The immunization week 19 consider booster immunization . The vaccine administer rotate site limbs abdomen . The study last approximately 12 - 24 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Female subject race histologically cytologically confirm stage IV breast cancer eligible . The cancer may newly diagnose metastatic relapse primary adjunctive therapy must require treatment change 2 month . Treatments antiestrogen therapy chemotherapy allow . The chemotherapy regimen contain steroid pre post supportive care medication . If subject investigational drug , drug must clear body period 4 week . Disease stag do accord American Joint Commission Cancer ( AJCC ) , sixth edition . Age 18 year old race ethnicity . ECOG Performance Status 0 1 . Subjects must active infection require treatment antibiotic . Subjects must significant medical , surgical psychiatric condition , require medication treatment , may interfere compliance treatment regimen . Subjects must diagnosis evidence organic brain syndrome , significant impairment basal cognitive function psychiatric disorder might preclude participation full protocol . Subjects must current malignancy . Subjects prior history time situ cancer , include lobular carcinoma breast situ , cervical cancer situ , atypical melanocytic hyperplasia Clark I melanoma situ basal squamous skin cancer eligible , provide diseasefree time registration . Subjects malignancy eligible continuously disease free ≥ 5 year prior time registration . Subjects must autoimmune disorder condition immunosuppression . This include , limited treat corticosteroid , include oral steroid ( i.e . prednisone , dexamethasone ) , continuous use topical steroid cream ointment steroidcontaining inhaler . Subjects systemic steroid require 6week washout period . Subjects discontinue use class medication least 6 week prior registration eligible , judgment treat physician , subject likely require class drug treatment period . Replacement dose steroid subject adrenal insufficiency allow . Women childbearing potential must pregnant ( negative serum pregnancy test must do 48 hour prior receive first dose study drug ) breastfeeding , due unknown effect peptide/mimotope vaccine fetus infant . Women childbearing potential must counsel use accept effective method contraception ( include abstinence ) treatment period 18 month complete discontinue treatment . Accepted method include oral contraceptive , barrier method , Intrauterine Devices ( IUDs ) , abstinence . Subjects must obtain white blood cell ( WBC ) count ≥ 3,000/mm3 platelet count ≥ 100,000/mm3 within 2 week prior registration . Subjects must serum glutamicoxaloacetic transaminase ( SGOT ) /aspartate aminotransferase test ( AST ) bilirubin ≤ 2 x institutional upper limit ( IUL ) normal serum creatinine ≤ 1.8 mg/dl , obtain within 2 week prior registration . Subjects must immunocompetent measured responsiveness two recall antigen skin test . All subject wish participate study must sign informed consent approve UAMS Institutional Review Board ( IRB ) . Laboratory test must complete within 2 week first dose .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>